PRISM BioLab Co. LTD

PRISM BioLab Co., Ltd. is a biotechnology company that researches and develops pharmaceuticals using its proprietary drug discovery platform, PepMetics Technology. Its pipeline includes E7386, which targets CBP/beta-catenin and is in Phase II clinical trials for cancer, and PRI724, also targeting CBP/beta-catenin, which is in Phase II clinical trials for cirrhosis. The company has a strategic collaboration with Receptor.AI Inc. to develop an AI-integrated drug discovery platform. Founded in 2006, PRISM BioLab is based in Fujisawa, Japan.